# Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Head and Neck Squamous Cell Carcinoma (REDUCTION-I)

> **NCT05582265** · PHASE3 · RECRUITING · sponsor: **Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University** · enrollment: 537 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinomas

## Interventions

- **DRUG:** Tislelizumab（neoadjuvant）
- **DRUG:** Cisplatin （neoadjuvant）
- **DRUG:** Nab-paclitaxel （neoadjuvant）
- **PROCEDURE:** Surgical resection
- **DRUG:** Cisplatin（adjuvant）
- **DRUG:** Tislelizumab（adjuvant）
- **RADIATION:** Radiation
- **DRUG:** Carboplatin (neoadjuvant）
- **DRUG:** Carboplatin (adjuvant）

## Key facts

- **NCT ID:** NCT05582265
- **Lead sponsor:** Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-10-28
- **Primary completion:** 2028-10
- **Final completion:** 2030-10
- **Target enrollment:** 537 (ESTIMATED)
- **Last updated:** 2024-05-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05582265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05582265, "Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Head and Neck Squamous Cell Carcinoma (REDUCTION-I)". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT05582265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*